Tecelra converts to full FDA approval and expands to pediatric synovial sarcoma

Sponsor: US WorldMeds
Drug: Tecelra · afamitresgene autoleucel
Indication: Adults and paediatric patients 12 years and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumour expresses the MAGE-A4 antigen

FDA converted Tecelra's 2024 accelerated approval to full (traditional) approval and expanded the indication to include patients as young as 12 years — the first engineered T-cell therapy for a solid tumour approved for a paediatric population. Full approval was granted on the basis of the SPEARHEAD-1 confirmatory Phase 2 trial (n=137) which produced an overall response rate of 43.8% (complete responses 3.6%) in HLA-A*02-eligible, MAGE-A4-expressing advanced synovial sarcoma. Sponsor is US WorldMeds, which acquired Tecelra's U.S. commercial rights from Adaptimmune.

Read original at prnewswire.com ↗

Background Drug-class context · Wikipedia

Synovial sarcoma is a rare, aggressive soft-tissue sarcoma driven by the SS18::SSX gene fusion, occurring most commonly in adolescents and young adults with peak incidence in the third decade. Approximately 800–1,000 new cases are diagnosed annually in the United States; overall five-year survival is ~50% but drops to ~10–20% in metastatic disease. First-line management for advanced disease is anthracycline-based chemotherapy; second-line options are limited and produce response rates typically below 20%. Afamitresgene autoleucel (Tecelra) is an autologous engineered T-cell therapy: a patient's own T cells are transduced ex vivo with a lentiviral vector encoding an affinity-enhanced T-cell receptor (SPEAR) that recognises the MAGE-A4 peptide 230–239 presented by HLA-A*02 class I molecules. Because MAGE-A4 is expressed in most synovial sarcomas and only in immune-privileged tissues (testis, placenta), it functions as a tumour-restricted target. Tecelra received FDA accelerated approval in August 2024 as the first engineered T-cell therapy for a solid tumour, contingent on confirmatory data. The June 2026 full-approval conversion is based on the SPEARHEAD-1 confirmatory Phase 2 study (n=137 treated adult patients with advanced synovial sarcoma) which demonstrated a 43.8% overall response rate with 3.6% complete responses. The paediatric indication expansion (12+) is supported by pharmacokinetic modelling and safety data extrapolated from the adult cohort. US WorldMeds acquired Tecelra's U.S. commercial rights from Adaptimmune Therapeutics in 2025; Adaptimmune retains manufacturing and non-U.S. commercialisation.

Source: Wikipedia · CC BY-SA

Topic solid-tumour cell therapy

Share LinkedIn X Bluesky